Vivoryon Therapeutics « Terug naar discussie overzicht

Probiodrug 2019

3.116 Posts, Pagina: « 1 2 3 4 5 6 ... 77 78 79 80 81 82 83 84 85 86 87 ... 152 153 154 155 156 » | Laatste
[verwijderd]
0
[Modbreak IEX: Gelieve elkaar niet persoonlijk aan te vallen, een aantal berichten is bij dezen verwijderd.]
[verwijderd]
0
quote:

DeZwarteRidder schreef op 15 april 2019 16:52:

Zal ik doorgaan met het plaatsen van berichten van Probio uit het verleden....???

Ik heb nog nooit een bedrijf gezien met zoveel mislukkingen.
Je bent blijkbaar geen biotech-specialist...
DeZwarteRidder
0
ze hebben zelfs een bedrijf overgenomen en die overname is totaal mislukt:
==========================================================================
Archive: 2007

We are committed to open and transparent communications with the investment community. Probiodrug’s announcements will be made mainly in English.
=========================================================================
Probiodrug AG Announces Changes to Supervisory Board and Appointment of Hendrik Liebers to Chief Financial Officer

Published: 17.07.07

Dr. Christoph Schröder, Dr. Erich Platzer and Dr. Dinnies von der Osten join Supervisory Board Halle (Saale) and Munich, Germany // Probiodrug AG, a developer of small molecule inhibitors against inflammatory and neurodegenerative diseases, today announced the appointment of Hendrik Liebers to Chief Financial Officer, effective June 1, 2007. In the context of the recent […]

Tagged with: press release , probiodrug
Read more
=======================================================================
Probiodrug AG Acquires Ingenium Pharmaceuticals AG to Form an Integrated Biopharmaceutical Company

Published: 25.06.07

Combined Entity Raises Euro 20.6 Million in Series A Funding Halle (Saale) and Munich, Germany // Probiodrug AG, a developer of small molecule inhibitors against inflammatory and neurodegenerative diseases, has acquired Ingenium Pharmaceuticals AG, a discovery and development company focused on inflammatory diseases, both companies announced today. The combined entity has simultaneously closed a Series […]

Tagged with: press release , probiodrug
====================================================================
Read more
Probiodrug Closes a EUR 10.6 Million (US$ 13.4 million) Series C Financing Round

Published: 15.06.07

Halle (Saale) and Munich , Germany // Probiodrug AG Privately held Probiodrug AG of Halle/Saale, Germany, announced today the closing of its Series C Financing Round raising a total of EUR 10.6 million (US$ 13.4 million). This financing brings the total funds available to Probiodrug to over EUR 19 million (US$ 24 million). The proceeds […]

Tagged with: press release , probiodrug
Read more
[verwijderd]
0
quote:

De opa van Juul schreef op 15 april 2019 15:37:

[...]

Die man is niet goed hoor, dadelijk komt hij nog met nieuws uit de middeleeuwen als hij maar gelijk krijgt.
2003 is al bijna de Middeleeuwen :-)
Zoooo'n enorm lachwekkende 'ridder' is echt zeer zeldzaam!
Fijne avond en proost maar weer ;-)
DeZwarteRidder
0
11 jaar verder en geen zak bereikt:
--------------------------------------------------------------------------
Archive: 2008

We are committed to open and transparent communications with the investment community. Probiodrug’s announcements will be made mainly in English.
=========================================================================
US PTO granting Probiodrug a Further Medical Use Patent for the Inhibition of the Enzyme Glutaminyl Cyclase (QC)

Published: 10.12.08

Halle/Saale, December 10, 2008 — Probiodrug AG (Probiodrug), a developer of small molecule inhibitors for the treatment of inflammatory and neurodegenerative diseases, announced today that the United States Patent Office issued to Probiodrug the US patent no. 7,462,599 covering compounds and methods for the inhibition of the conversion of substrates of the enzyme glutaminyl cyclase […]

Tagged with: press release , probiodrug
Read more
======================================================================
Probiodrug to Present an Update on QC Inhibition as Potential New Treatment for Alzheimer’s Disease at the Society for Neuroscience Meeting 2008, Nov. 15-19, 2008, Washington, DC

Published: 04.11.08

Attenuation of Alzheimer’s disease-like pathology by inhibition of glutaminyl cyclase catalyzed pyroglutamate Aß formation in transgenic animals Halle/Saale, November 15, 2008 — Probiodrug AG (Probiodrug), a developer of small molecule inhibitors for the treatment of neurodegenerative and inflammatory diseases, announced today that the company will present an update on its human glutaminyl cyclase inhibition program […]

Tagged with: press release , probiodrug
Read more
=====================================================================
Nature Medicine Publication Elucidating Probiodrug´s New Treatment Paradigm for Alzheimer’s disease

Published: 28.09.08

Halle/Saale, September 29th, 2008, 08:00 Uhr MESZ — Probiodrug AG (Probiodrug), a developer of small molecule inhibitors for the treatment of inflammatory and neurodegenerative diseases, today announced the publication of in vivo data in Nature Medicine supporting the finding that inhibition of the enzyme Glutam(in)yl Cyclase (QC) can be considered as a potentially causative new […]

Tagged with: press release , probiodrug
Read more
========================================================================
Nature Medicine Publikation erläutert Probiodrugs neues Paradigma zur Behandlung der Alzheimer-Erkrankung

Published:

Halle/Saale, 29. September 2008, 08:00 Uhr MESZ — Die Probiodrug AG, ein biopharmazeutisches Unternehmen mit Schwerpunkt auf der Entwicklung von niedermolekularen Inhibitoren im Bereich entzündlicher und neurodegenerativer Krankheiten, hat heute die Publikation von in vivo Daten in der Zeitschrift Nature Medicine bekannt gegeben, die belegen, dass die Blockade des Enzyms Glutaminylzyklase (QC) sich möglicherweise zur […]

Tagged with: press release , probiodrug
Read more
=========================================================================
Probiodrug to Present Potential New Treatment for Alzheimer’s Disease

Published: 14.08.08

Update on Novel QC inhibitors at the American Chemical Society 236th National Meeting, 2008 Halle/Saale // Probiodrug AG (Probiodrug), a developer of small molecule inhibitors for the treatment of inflammatory and neurodegenerative diseases, announced today that the company will present an update on its human glutaminyl cyclase inhibitor program for the treatment of Alzheimer’s disease […]

Tagged with: press release , probiodrug
Read more
========================================================================
Probiodrug announces appointment of Prof Dr Harald Labischinski and Dr Jonathan David Turner to its Board of Directors

Published: 14.07.08

Halle (Saale) // Probiodrug AG (Probiodrug), a developer of small molecule inhibitors for the treatment of inflammatory and neurodegenerative diseases, today announced that Prof Dr Harald Labischinski and Dr. Jonathan David Turner have been appointed to Probiodrug´s Board of Directors. They will join the current Board of Directors consisting of Dr Christoph Schröder, TVM Capital, […]

Tagged with: press release , probiodrug
Read more
Alex69
0
Hoe dan ook. Het eerstvolgende koersdoel van 5.76 is op slotbasis bereikt. De volgende halte omhoog is 7.88
[verwijderd]
0
DeZwarteRidder
0
Het motto van Probio: veel geld ophalen en alles uitgeven aan projecten (en personeel) die veel geld kosten en niks opleveren:
-------------------------------------------------------------------------
archive: 2009

We are committed to open and transparent communications with the investment community. Probiodrug’s announcements will be made mainly in English.
------------------------------------------------------------------------
Probiodrug Closes Series B Financing Round exceeding EUR 36 Million (US$54 Million)

Published: 02.11.09

Company wins BB Biotech and Edmond de Rothschild Investment Partners as co – lead investors, joined by LSP Life Science Partners, Biogen Idec New Ventures and existing investors Halle/Saale, November 2nd, 2009 — Probiodrug AG (Probiodrug), a biotech company developing novel concepts and products for the treatment of neurodegenerative and inflammatory diseases with a particular […]

Tagged with: press release , probiodrug
Read more
=========================================================================
Probiodrug to Present an Update on QC Inhibition as Potential New Treatment for Alzheimer’s Disease at the International Conference on Alzheimer Disease – ICAD – 2009 in Vienna, Austria, July 11-16

Published: 11.07.09

Pyroglutamated Aß and Neuroinflammation: Targeting fundamentals of AD pathogenesis by QC inhibition. Halle / Saale, July 11, 2009 — Probiodrug AG (Probiodrug), a developer of small molecule inhibitors for the treatment of neurodegenerative and inflammatory diseases, announced today that the company will present an update on its human glutaminyl cyclase inhibition program for the treatment […]

Tagged with: press release , probiodrug
Read more
==========================================================================
Probiodrug Announces Validity of European Patent Covering Use of DP4 inhibitors for the Treatment of Anxiety

Published: 15.05.09

Halle/Saale, May 15, 2009 — Probiodrug AG (Probiodrug), a developer of small molecule inhibitors for the treatment of inflammatory and neurodegenerative diseases, announced today that no opposition has been filed against its European patent EP1 328 271 B1 covering “Treatment of Neurological and Neuropsychological Disorders”. The patent is now valid and can be enforced in […]

Tagged with: press release , probiodrug
Read more
==========================================================================
Probiodrug to Present an Update on QC Inhibition as Potential New
Treatment for Alzheimer’s Disease at the 9th international conference AD/PD 2009 in Prague, Czech Republic, March 11-15.

Published: 10.03.09

Pyroglutamated Aß and Neuroinflammation: Targeting fundamentals of AD pathogenesis by QC inhibition. Halle/Saale, March 11, 2009 — Probiodrug AG (Probiodrug), a developer of small molecule inhibitors for the treatment of neurodegenerative and inflammatory diseases, announced today that the company will present an update on its human glutaminyl cyclase inhibition program for the treatment of Alzheimer’s […]

Tagged with: press release , probiodrug
Read more
=========================================================================
[verwijderd]
0
[Modbreak IEX: Gelieve elkaar niet persoonlijk aan te vallen, een aantal berichten is bij dezen verwijderd.]
[verwijderd]
0
Men had veel gelukt voor je het weet sloten we rood. Morgen is alles anders en het kan zo maar naar de 3 euro of niet ridder
[verwijderd]
0
quote:

DeZwarteRidder schreef op 15 april 2019 18:13:

[...]
de ouders van Neet:

Bijlage:
[verwijderd]
0
o ja zeker en morgen gaat het regenen met tranen en tuiten voor meneer ......
Bijlage:
DeZwarteRidder
0
quote:

neet schreef op 15 april 2019 18:05:

om te gieren weer meneer DZW
vroeger hadden we ook de ijstijd ijskonijn!!!!!
Kun je nagaan hoelang het duurt om een werkzaam geneesmiddel te maken en daar ook nog geld mee te verdienen.
20 jaar is het absolute minimum.
[verwijderd]
0
quote:

neet schreef op 15 april 2019 18:09:

was weer een mooie dag voor ons pareltje voor 2019
En de 'shuffle' gaat nog wel even door.
Dzr heeft her nog steeds niet in de gaten, zeldzaam gevalletje, wel erg amusant.
Fijne avond en proost
DeZwarteRidder
0
fabuleus nieuws en geen stap verder...!!
PS: let op de peperdure adviseurs en personeel, die allemaal weer zijn opgehoepeld:
------------------------------------------------------------------------
Archive: 2010

We are committed to open and transparent communications with the investment community. Probiodrug’s announcements will be made mainly in English.
========================================================================
Probiodrug Appoints Prof Cynthia Lemere to its Scientific Advisory Board

Published: 15.11.10

Halle/Saale, November 15, 2010 — Probiodrug AG (Probiodrug), a biotech company developing novel concepts and products for the treatment of neurodegenerative and inflammatory diseases with a particular focus on Alzheimer’s disease, today announced the appointment of Prof Cynthia Lemere, PhD, to the Company’s Scientific Advisory Board. Cynthia Lemere is Associate Professor of Neurology at the […]

Tagged with: press release , probiodrug
Read more
=========================================================================
Probiodrug Hosts International Symposium “Neurodegenerative Disorders During Aging – Contemporary Research and New Therapies”

Published: 12.11.10

Halle/Saale, November 12, 2010 — Probiodrug AG (Probiodrug), a biotech company developing novel concepts and products for the treatment of neurodegenerative and inflammatory diseases with a particular focus on Alzheimer’s disease, today announced it will host an international symposium on the latest insights in neurodegenerative disorders during aging and new therapeutic strategies to combat these […]

Tagged with: press release , probiodrug
Read more
-------------------------------------------------------------------------
Probiodrug to Present at the Lazard Capital Markets 7th Annual Healthcare Conference in New York City

Published: 08.11.10

Halle/Saale, Nov. 08, 2010 — Probiodrug AG (Probiodrug), a biotech company developing novel products for the treatment of neurodegenerative and inflammatory diseases with a particular focus on Alzheimer’s disease, today announced that it has been invited to present at the Lazard Capital Markets 7th Annual Healthcare Conference, which will take place in New York, NY, […]

Tagged with: press release , probiodrug
Read more
==========================================================================
Probiodrug to Present Novel Findings on the Pathogenesis of Alzheimer’s Disease at Neuroscience 2010

Published: 01.11.10

Probiodrug to Present Novel Findings on the Pathogenesis of Alzheimer’s Disease at Neuroscience 2010 Halle/Saale, Nov 1st, 2010 — Probiodrug AG (Probiodrug), a biotech company developing novel products for the treatment of neurodegenerative and inflammatory diseases with a particular focus on Alzheimer’s disease, today announced that it will present novel findings on the pathomechanism of […]

Tagged with: press release , probiodrug
Read more
=========================================================================
Probiodrug Appoints Kumar Srinivasan as Chief Business Officer

Published: 13.09.10

Halle/Saale, Sept.13, 2010 — Probiodrug AG (Probiodrug), a biotech company developing novel products for the treatment of neurodegenerative and inflammatory diseases with a particular focus on Alzheimer’s disease, today announced the appointment of Dr Kumar Srinivasan, MBA, to the position of Chief Business Officer. Kumar Srinivasan joins Probiodrug from Wyeth Pharmaceuticals, a division of Wyeth, […]

Tagged with: press release , probiodrug
Read more
=========================================================================
Probiodrug to Present at ICAD Alzheimer Conference New disease mechanism and therapeutic strategy selected as “hot topic”

Published: 08.07.10

Halle/Saale, July 8, 2010 — Probiodrug AG (Probiodrug), a biotech company developing novel concepts and products for the treatment of neurodegenerative and inflammatory diseases with a particular focus on Alzheimer’s disease, today announced that the Company will present four posters featuring its latest research results about a unique pathway possibly involved in the onset and […]

Tagged with: press release , probiodrug
Read more
=========================================================================
[verwijderd]
0
quote:

DeZwarteRidder schreef op 15 april 2019 18:52:

fabuleus nieuws en geen stap verder...!!
PS: let op de peperdure adviseurs en personeel, die allemaal weer zijn opgehoepeld:
------------------------------------------------------------------------
Archive: 2010

We are committed to open and transparent communications with the investment community. Probiodrug’s announcements will be made mainly in English.
========================================================================
Probiodrug Appoints Prof Cynthia Lemere to its Scientific Advisory Board

Published: 15.11.10

Halle/Saale, November 15, 2010 — Probiodrug AG (Probiodrug), a biotech company developing novel concepts and products for the treatment of neurodegenerative and inflammatory diseases with a particular focus on Alzheimer’s disease, today announced the appointment of Prof Cynthia Lemere, PhD, to the Company’s Scientific Advisory Board. Cynthia Lemere is Associate Professor of Neurology at the […]

Tagged with: press release , probiodrug
Read more
=========================================================================
Probiodrug Hosts International Symposium “Neurodegenerative Disorders During Aging – Contemporary Research and New Therapies”

Published: 12.11.10

Halle/Saale, November 12, 2010 — Probiodrug AG (Probiodrug), a biotech company developing novel concepts and products for the treatment of neurodegenerative and inflammatory diseases with a particular focus on Alzheimer’s disease, today announced it will host an international symposium on the latest insights in neurodegenerative disorders during aging and new therapeutic strategies to combat these […]

Tagged with: press release , probiodrug
Read more
-------------------------------------------------------------------------
Probiodrug to Present at the Lazard Capital Markets 7th Annual Healthcare Conference in New York City

Published: 08.11.10

Halle/Saale, Nov. 08, 2010 — Probiodrug AG (Probiodrug), a biotech company developing novel products for the treatment of neurodegenerative and inflammatory diseases with a particular focus on Alzheimer’s disease, today announced that it has been invited to present at the Lazard Capital Markets 7th Annual Healthcare Conference, which will take place in New York, NY, […]

Tagged with: press release , probiodrug
Read more
==========================================================================
Probiodrug to Present Novel Findings on the Pathogenesis of Alzheimer’s Disease at Neuroscience 2010

Published: 01.11.10

Probiodrug to Present Novel Findings on the Pathogenesis of Alzheimer’s Disease at Neuroscience 2010 Halle/Saale, Nov 1st, 2010 — Probiodrug AG (Probiodrug), a biotech company developing novel products for the treatment of neurodegenerative and inflammatory diseases with a particular focus on Alzheimer’s disease, today announced that it will present novel findings on the pathomechanism of […]

Tagged with: press release , probiodrug
Read more
=========================================================================
Probiodrug Appoints Kumar Srinivasan as Chief Business Officer

Published: 13.09.10

Halle/Saale, Sept.13, 2010 — Probiodrug AG (Probiodrug), a biotech company developing novel products for the treatment of neurodegenerative and inflammatory diseases with a particular focus on Alzheimer’s disease, today announced the appointment of Dr Kumar Srinivasan, MBA, to the position of Chief Business Officer. Kumar Srinivasan joins Probiodrug from Wyeth Pharmaceuticals, a division of Wyeth, […]

Tagged with: press release , probiodrug
Read more
=========================================================================
Probiodrug to Present at ICAD Alzheimer Conference New disease mechanism and therapeutic strategy selected as “hot topic”

Published: 08.07.10

Halle/Saale, July 8, 2010 — Probiodrug AG (Probiodrug), a biotech company developing novel concepts and products for the treatment of neurodegenerative and inflammatory diseases with a particular focus on Alzheimer’s disease, today announced that the Company will present four posters featuring its latest research results about a unique pathway possibly involved in the onset and […]

Tagged with: press release , probiodrug
Read more
=========================================================================
je bent er maar druk mee man al dat gezoek op google
tip heeft geen zin man zonde van je tijd
DeZwarteRidder
0
quote:

neet schreef op 15 april 2019 19:07:

[...]je bent er maar druk mee man al dat gezoek op google
tip heeft geen zin man zonde van je tijd
Ik hoef niks te zoeken, alles staat op de website van Probiodrug.
[verwijderd]
0
het enige wat bij telt en daar gaat het om geld verdienen op de beurs en het liefst zoveel en zo snel mogelijk
wat een bedrijf doet of niet doet boeit me niet zo
einde van het jaar moet ik weer mijn doel halen
en laat probio nou een mooie prooi zijn voor mij en nog vele anderen behalve jij dan want jij gelooft alleen in jezelf toch kerel
sinterklaas en de kerstman komen bij jou met lege jute zakken
en de paashaas komt bij mij met gouden eieren en dat is al heel snel.
DeZwarteRidder
0
quote:

neet schreef op 15 april 2019 19:11:

het enige wat bij telt en daar gaat het om geld verdienen op de beurs en het liefst zoveel en zo snel mogelijk
wat een bedrijf doet of niet doet boeit me niet zo
einde van het jaar moet ik weer mijn doel halen
en laat probio nou een mooie prooi zijn voor mij en nog vele anderen behalve jij dan want jij gelooft alleen in jezelf toch kerel
Dat het bij jou alleen om geld gaat wisten we al.
3.116 Posts, Pagina: « 1 2 3 4 5 6 ... 77 78 79 80 81 82 83 84 85 86 87 ... 152 153 154 155 156 » | Laatste
Aantal posts per pagina:  20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Detail

Vertraagd 4 mrt 2025 10:18
Koers 1,970
Verschil -0,020 (-1,01%)
Hoog 1,980
Laag 1,960
Volume 20.621
Volume gemiddeld 155.105
Volume gisteren 66.220

EU stocks, real time, by Cboe Europe Ltd.; Other, Euronext & US stocks by NYSE & Cboe BZX Exchange, 15 min. delayed
#/^ Index indications calculated real time, zie disclaimer, streaming powered by: Infront